低分子量肝素治疗急性脑梗死68例临床观察  

Clinical observation of 68 cases of acute cerebral infarction treated by low-molecular-weight heparin

作　　者：杨映娟[1] 金钦华[2] 

机构地区：[1]广东省普宁市华侨医院内科,515300 [2]汕头大学附属第二医院神经内科

出　　处：《中国综合临床》2006年第6期485-486,共2页Clinical Medicine of China

摘　　要：目的评价低分子量肝素(LMWH)对急性脑梗死的近期疗效及安全性。方法急性脑梗死患者68例,随机分为治疗组和对照组各34例,均使用低分子右旋糖酐和丹参进行基础治疗。治疗组加用LMWH3200U,腹壁皮下注射,每12小时1次,连用10d,于停药后10d观察疗效。结果治疗组总有效率为85.3%,明显优于对照组的66.3%(P<0.05)。治疗组继发无症状性颅内出血1例。未发现血小板减少症等副作用。结论LMWH治疗急性脑梗死安全、可靠。Objective To investigate the short-time efficacy and safety of low-molecular-weight heparin （ LMWH ） in the treatment of acute cerebral infarction （ ACI ）. Methods 68 cases of ACI were randomly divided into treatment group and control group （ n = 34 for each ）, who were treated by low-molecular-weight dextran and Danshen. The treatment group was given 3200 U, once every 12 hours,LMWH subcutaneously for 10 days, and the therapeutic effect was observed 10 days after withdrawing of medicine. Results The total effective rate was 85.3% in the treatment group,which was obviously greater than that of control group （ 66.3% ） （ P 〈 0.05 ）. Secondary asymptomatic intracranial hemorrhage occurred in 1 case of the treatment group. No serious complication was found like thrombocytopenia. Conclusion LMWH is safe and reliable for the treatment of acute cerebral infarction.

关 键 词：急性脑梗死 低分子量肝素 

分 类 号：R743.33[医药卫生—神经病学与精神病学]